

## Document details

[Back to results](#) | 1 of 8 [Next](#) >

[Export](#)
[Download](#)
[Print](#)
[E-mail](#)
[Save to PDF](#)
[Add to List](#)
[More...](#)
[Full Text](#)
[View at Publisher](#)

Reviews in the Neurosciences

Volume 28, Issue 7, 26 October 2017, Pages 811-823

**Interactions between cannabis and schizophrenia in humans and rodents** (Article)

 Moustafa, A.A.<sup>2b</sup>, Salama, M.<sup>c</sup>, Peak, R.<sup>a</sup>, Tindle, R.<sup>a</sup>, Salem, A.<sup>a</sup>, Keri, S.<sup>det</sup>, Misiak, B.<sup>g</sup>, Frydecka, D.<sup>h</sup>, Mohamed, W.<sup>h</sup>
<sup>a</sup>School of Social Sciences and Psychology, Western Sydney University, Sydney, NSW, Australia<sup>b</sup>Marcus Institute for Brain and Behaviour, Western Sydney University, Sydney, NSW, Australia<sup>c</sup>School of Medicine, Mansoura University, Mansoura, Egypt
[View additional affiliations](#)

## Abstract

[View references \(137\)](#)

In this review, we provide an overview of the relationship between cannabis use and the development of schizophrenia, using both animal and human studies. We further discuss the potential neural mechanism that may mediate the relationship between cannabis use and schizophrenia symptoms. We finally provide clinical implications and future studies that can further elucidate the relationship between cannabis and schizophrenia. © 2017 Walter de Gruyter GmbH, Berlin/Boston 2017.

## Reaxys Database Information

[View Compounds](#)

## Author keywords

[cannabis](#)
[endocannabinoid receptors](#)
[negative symptoms](#)
[positive symptoms](#)
[schizophrenia](#)

## Indexed keywords

EMTREE drug terms:

[anandamide](#)
[cannabis](#)
[endocannabinoid](#)

EMTREE medical terms:

[anxiety disorder](#)
[Article](#)
[cannabis use](#)
[clinical feature](#)
[cognition](#)
[cognitive defect](#)
[disease association](#)
[disease course](#)
[disease exacerbation](#)
[dose response](#)
[drug dependence](#)
[human](#)
[memory disorder](#)
[negative syndrome](#)
[nerve cell](#)
[nonhuman](#)
[positive syndrome](#)
[prevalence](#)
[priority journal](#)
[psychophysiology](#)
[psychosomatic disorder](#)
[schizophrenia](#)
[self medication](#)
[stress](#)

## Chemicals and CAS Registry Numbers:

anandamide, 94421-68-8; cannabis, 8001-45-4, 8063-14-7

ISSN: 03341763

CODEN: RNEUE

Source Type: Journal

Original language: English

DOI: 10.1515/revneuro-2016-0083

Document Type: Article

Publisher: Walter de Gruyter GmbH

[References \(137\)](#)
[View in search results format](#)

## Metrics

0 Citations in Scopus

0 Field-Weighted Citation Impact



PlumX Metrics

Usage, Captures, Mentions, Social Media and Citations beyond Scopus.

## Cited by 0 documents

Inform me when this document is cited in Scopus:



## Related documents

A Study of the Impact of Cannabis on Doses of Discharge Antipsychotic Medication in Individuals with Schizophrenia or Schizoaffective Disorder

 Babatope, T., Chotalia, J., Elkhatib, R. (2016) *Psychiatric Quarterly*

## Therapeutic Potential

 Manseau, M.W., Goff, D.C. (2015) *Neurotherapeutics*

Cannabis and Psychosis: Correlation, Causality, and Consequences

 Basu, D., Parakh, P. (2017) *Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment*
[View all related documents based on references](#)
[Find more related documents in Scopus based on:](#)
[Authors](#)
[Keywords](#)